Delcath Systems to Participate in Investor Conferences, Focus on Liver Cancer Treatment

Delcath Systems, a leading interventional oncology company, will participate in two investor conferences in September 2025 to strengthen market presence and investor relations. The company specializes in liver cancer treatment with its products HEPZATO KIT and CHEMOSAT. HEPZATO KIT is FDA-approved for treating metastatic uveal melanoma in the US, while CHEMOSAT is approved for conducting percutaneous hepatic perfusion procedures in Europe. The company's market cap is valued at $372.55 million with notable institutional ownership at 52.75%.

Delcath Systems, Inc. (Nasdaq: DCTH), a leading interventional oncology company, has announced its participation in two upcoming investor conferences in September 2025. The company aims to strengthen its market presence and investor relations by engaging with key stakeholders during these events. Delcath Systems specializes in the treatment of primary and metastatic liver cancers, with its proprietary products HEPZATO KIT™ and CHEMOSAT® Hepatic Delivery System for Melphalan.

The company's management will attend the following investor conferences:

1. Wells Fargo Healthcare Conference on Thursday, September 4, 2025, in Boston, MA.
2. H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025, in New York, NY.

HEPZATO KIT™, a combination drug and device product, is FDA-approved for treating metastatic uveal melanoma (mUM) in the United States. It is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a percutaneous hepatic perfusion (PHP) procedure. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT.

Delcath Systems recently announced the first patient dosing in its global Phase 2 Clinical Trial evaluating HEPZATO™ in combination with standard of care (SOC) treatment for liver-dominant metastatic colorectal cancer (mCRC). The trial will enroll approximately 90 patients across the United States and Europe. Results from the trial’s primary endpoint, hepatic progression-free survival (hPFS), are anticipated by mid-2028, while overall survival (OS) is expected in late 2028.

Delcath Systems aims to provide a novel treatment option for patients with liver-dominant mCRC, a patient population with limited therapeutic alternatives. The company estimates that the total addressable market for liver-dominant mCRC receiving third-line treatment is between 6,000 and 10,000 patients annually in the United States.

The company's market cap is valued at $372.55 million, with notable institutional ownership at 52.75% [1].

References:
[1] https://finance.yahoo.com/news/delcath-systems-participate-upcoming-investor-123000438.html
[2] https://www.biospace.com/press-releases/delcath-systems-to-participate-in-upcoming-september-2025-investor-conferences
[3] https://investors.delcath.com/news-releases/news-release-details/delcath-systems-announces-first-patient-dosed-phase-2-clinical